Brera Holdings PLC, also known as Solmate Infrastructure and trading on Nasdaq as SLMT, recently achieved a surprise re-election of all five incumbent directors at its 2026 Annual General Meeting held in Abu Dhabi. This decision came despite a strong recommendation from an independent proxy advisor to vote against the current board members. A total of 71.49% of outstanding shares were represented during the vote, with support for the directors ranging from 62% to nearly 70%. This outcome strongly challenged the opposition efforts that had accumulated over several weeks.
A notable development preceded the AGM when RBCH Ltd., the largest external shareholder with a stake greater than 10%, filed a derivative lawsuit against the board. This legal action, initiated just days before the AGM, alleged breaches of fiduciary duty and self-dealing practices related to a registered direct offering executed in May 2026. In particular, the lawsuit claimed that two board members purchased shares at a price that significantly eroded the value for other shareholders, amounting to an $18 million dilution.
Despite the proxy advisor's adverse recommendation, institutional shareholders largely opted to maintain the existing board. The governance issues raised throughout the dispute, including board independence and a poison pill arrangement introduced earlier that year, persist and still warrant close attention by investors and analysts alike.
The implications of the legal proceedings remain significant. The derivative lawsuit is currently active, with RBCH Ltd. retaining more than 10% of company shares. Investors should monitor the potential impact of the lawsuit on share value, especially if evidence emerges indicating that the offering favored insiders at the expense of regular shareholders. Such developments could influence future negotiations and strategic decisions within the company.